Showing results (491-500 of 577) with videos related to

Sort By:
Pageof 58
Journal of Immigrant and Minority Health|March 7, 2019
Mortality Paradox of Older Italian-Born Men in Australia: The Concord Health and Ageing in Men ProjectFiona F Stanaway, Fiona M Blyth, Vasi Naganathan, et al.
Gerodontology|October 8, 2019
Frailty and oral health: Findings from the Concord Health and Ageing in Men ProjectEduardo Valdez, Fredrick A Clive Wright, Vasi Naganathan, et al.
Journal of Clinical Epidemiology|June 30, 2012
Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomesDanijela Gnjidic, Sarah N Hilmer, Fiona M Blyth, et al.
Internal Medicine Journal|February 12, 2005
Determinants of health-related quality of life in institutionalised older persons in northern SydneyY Y Sitoh, T C Lau, J Zochling, et al.
Pain|October 7, 2008
Pain, frailty and comorbidity on older men: the CHAMP studyFiona M Blyth, Stephane Rochat, Robert G Cumming, et al.
Bioorganic & Medicinal Chemistry Letters|April 25, 2006
Modulators of the human CCR5 receptor. Part 3: SAR of substituted 1-[3-(4-methanesulfonylphenyl)-3-phenylpropyl]-piperidinyl phenylacetamidesJohn G Cumming, Simon J Brown, Anne E Cooper, et al.
Bioorganic & Medicinal Chemistry Letters|May 22, 2012
The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivityJohn G Cumming, Justin F Bower, David Waterson, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|September 8, 2010
Determinants of serum-induced SIRT1 expression in older men: the CHAMP studyDavid G Le Couteur, Vicky L Benson, Aisling C McMahon, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|February 7, 2021
Dietary and supplemental antioxidant intake and risk of major adverse cardiovascular events in older men: The concord health and ageing in men projectArpita Das, Robert G Cumming, Vasi Naganathan, et al.
Bioorganic & Medicinal Chemistry Letters|May 22, 2012
The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesDearg S Brown, John G Cumming, Paul Bethel, et al.
Pageof 58